Phase I, Dose-Escalation, Safety, Pharmacokinetic, And Pharmacodynamic Study Of Single-Agent Pf-03758309, An Oral Pak Inhibitor, In Patients With Advanced Solid Tumors.

L. R. Mileshkin,Lee S. Rosen,T. Blumenkopf,Aurora Breazna, S. Darang, J. Davison,J. Gallo,Jonathan W. Goldman,D. D. Wang, S. Zhang,S. G. Eckhardt

JOURNAL OF CLINICAL ONCOLOGY（2011）

引用 5|浏览14

暂无评分

摘要

e13607^ Background: Abnormalities of the Rho family pathway are involved in different steps of malignant transformation and tumor progression. Of the many effector proteins that bind to active Rho ...

查看译文

关键词

oral pak inhibitor,pharmacokinetic,pharmacodynamic study,advanced solid tumors,dose-escalation,single-agent

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要